Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Aprocitentan

Generic Name: Aprocitentan

Brand Names: Jeraygo

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₁₄Br_₂N_₆O_₄S

CAS Number: 1103522-45-7

Unique Ingredient Identifier: MZI81HV01P

Overview

Aprocitentan is under investigation in clinical trial NCT03541174 (A Research Study to Show the Effect of Aprocitentan in the Treatment of Difficult to Control (Resistant) High Blood Pressure (Hypertension) and Find Out More About Its Safety).

Background

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

A Drug-drug Interaction Trial in Healthy Female Participants to Investigate the Effect of Aprocitentan on Combined Hormonal Contraceptives

Phase 1

Completed

Posted: 2025/01/29

Sponsor:Idorsia Pharmaceutic...

ID:NCT06799884

Bioequivalence Study of Different Aprocitentan Tablet Formulations

Phase 1

Completed

Posted: 2022/01/19

Sponsor:Idorsia Pharmaceutic...

ID:NCT05196399

To Study the Effect of Aprocitentan on the Electrical Activity of the Heart in Healthy Men and Women

Phase 1

Completed

Posted: 2020/02/24

Sponsor:Idorsia Pharmaceutic...

ID:NCT04281342

The Effect of Hepatic Impairment on Aprocitentan Pharmacokinetics

Phase 1

Completed

Posted: 2020/02/05

Sponsor:Idorsia Pharmaceutic...

ID:NCT04252495

A Research Study to Show Aprocitentan is Efficacious and Safe to Treat Patients With Uncontrolled Blood Pressure and Chronic Kidney Disease.

Phase 3

Withdrawn

Posted: 2019/11/14

Sponsor:Idorsia Pharmaceutic...

ID:NCT04162366

FDA Approved Products

TRYVIO

Manufacturer:Idorsia Pharmaceuticals Ltd

Route:ORAL

Strength:12.5 mg in 1 1

Approved: 2024/03/27

NDC:80491-0812

Singapore Approved Products

No Singapore products found for this drug

Related News

FDA Approves First TAVR Therapy for Asymptomatic Severe Aortic Stenosis Patients

22 days ago

Edwards Lifesciences' SAPIEN 3 platform has received FDA approval for treating asymptomatic patients with severe aortic stenosis, marking the first such approval for transcatheter aortic valve replacement in this patient population.

Aprocitentan Shows Significant Blood Pressure and Proteinuria Reduction in Black Patients with Resistant Hypertension

a month ago

Aprocitentan, a dual endothelin receptor antagonist, demonstrated clinically meaningful and sustained blood pressure reductions in Black patients with resistant hypertension when added to existing antihypertensive regimens.

FDA Removes REMS Requirement for TRYVIO, Simplifying Access to Novel Hypertension Treatment

2 months ago

The US FDA has eliminated the Risk Evaluation and Mitigation Strategy (REMS) requirement for TRYVIO (aprocitentan), determining that standard labeling is sufficient to communicate safety information.

Mineralys Therapeutics' Lorundrostat Advances to Phase 2 for Obstructive Sleep Apnea and Hypertension

4 months ago

Mineralys Therapeutics' lorundrostat receives FDA clearance for a Phase 2 trial targeting obstructive sleep apnea (OSA) in hypertensive patients.

FDA Approves Tryvio (aprocitentan) for Hypertension Treatment in Combination with Other Antihypertensives

6 months ago

The FDA approved aprocitentan (Tryvio) in March 2024, an endothelin receptor antagonist, for hypertension treatment when combined with other antihypertensive medications.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy